RT Journal Article
SR Electronic
T1 Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1-nCoV19 and BNT162b2: a prospective cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.19.21257334
DO 10.1101/2021.05.19.21257334
A1 Hillus, David
A1 Schwarz, Tatjana
A1 Tober-Lau, Pinkus
A1 Hastor, Hana
A1 Thibeault, Charlotte
A1 Kasper, Stefanie
A1 Helbig, Elisa T.
A1 Lippert, Lena J.
A1 Tscheak, Patricia
A1 Schmidt, Marie Luisa
A1 Riege, Johanna
A1 Solarek, André
A1 Kalle, Christof von
A1 Dang-Heine, Chantip
A1 Kopankiewicz, Piotr
A1 Suttorp, Norbert
A1 Drosten, Christian
A1 Bias, Harald
A1 Seybold, Joachim
A1 EICOV/COVIM Study Group
A1 Conrad, Claudia
A1 Steuer, Doris
A1 Gläser, Ute
A1 Sinnigen, Anne-Sophie
A1 Rubisch, Carolin
A1 Olk, Nadine
A1 Hasler, Lisbeth
A1 Sanchez-Rezza, Angela
A1 Kronenberg, Paolo
A1 Horn, Alexandra
A1 Koch, Willi
A1 Stubbemann, Paula
A1 Gabelich, Julie-Anne
A1 Münn, Friederike
A1 Tesch, Julia
A1 Mackeldanz, Petra
A1 Bergfeld, Leon
A1 Bleicker, Tobias
A1 Beheim-Schwarzbach, Jörn Ilmo
A1 Hiller, Anna
A1 Brumhard, Sophia
A1 Bardtke, Lara
A1 Pohl, Kai
A1 Wendisch, Daniel
A1 Georg, Philipp
A1 Treue, Denise
A1 Briesemeister, Dana
A1 Schlesinger, Jenny
A1 Hetey, Andreas
A1 Kegel, Luisa
A1 Richter, Annelie
A1 Al-Rim, Ben
A1 Maeß, Birgit
A1 Behn, Kerstin
A1 Lysi, Michelle
A1 Zvorc, Saskia
A1 Rönnefarth, Maria
A1 Schmidt, Sein
A1 Krannich, Alexander
A1 Schellenberger, Isabelle
A1 Schwanitz, Georg
A1 Schenkel, Viktoria
A1 Bethke, Norma
A1 Hülso, Claudia
A1 Dieckmann, Sebastian
A1 Peiser, Christian
A1 Kurth, Florian
A1 Corman, Victor Max
A1 Sander, Leif Erik
YR 2021
UL http://medrxiv.org/content/early/2021/06/02/2021.05.19.21257334.abstract
AB Objective to assess reactogenicity and immunogenicity of heterologous prime-boost immunisations of ChAdOx1-nCoV19 (Vaxzevria, ChAdOx) followed by BNT162b2 (Comirnaty, BNT) compared to homologous BNT/BNT immunisation.Design prospective, observational cohort study.Setting unicenter study in a cohort of health care workers at a tertiary care center in Berlin, Germany.Participants 340 health care workers immunised between 27 December 2020 and 21 May 2021 at Charité - Universitätsmedizin Berlin, GermanyMain outcome measures the main outcomes were reactogenicity assessed on days one, three, five and seven post prime and boost vaccination, and immunogenicity measured by serum SARS-CoV-2 full spike-, spike S1-, and spike RBD-IgG, virus neutralisation capacity, anti-S1-IgG avidity, and T cell reactivity measured by Interferon gamma release assay at 3-4 weeks post prime and boost immunisation.Results Heterologous ChAdOx/BNT booster vaccination was overall well-tolerated and reactogenicity was largely comparable to homologous BNT/BNT vaccination. Systemic reactions were most frequent after prime immunisation with ChAdOx (86%, 95CI: 79-91), and less frequent after homologous BNT/BNT (65%, 95CI: 56-72), or heterologous ChAdOx/BNT booster vaccination (48%, 95CI: 36-59). Serum antibody responses and T cell reactivity were strongly increased after both homologous and heterologous boost, and immunogenicity was overall robust, and comparable between both regimens in this cohort, with slightly increased S1-IgG avidity and T cell responses following heterologous booster immunisation.Conclusions Evidence of rare thrombotic events associated with ChAdOx has led to recommendation of a heterologous booster with mRNA vaccines for certain age groups in several European countries, despite a lack of robust safety and immunogenicity data for this vaccine regimen. This interim analysis provides evidence that the currently recommended heterologous ChAdOx/BNT immunisation regimen with 10-12 week vaccine intervals is well tolerated and slightly more immunogenic compared to homologous BNT/BNT vaccination with three week vaccine intervals. Heterologous prime-boost immunisation for COVID-19 may be generally applicable to optimise logistics and improve immunogenicity and to mitigate potential intermittent supply shortages for individual vaccines.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialEudraCT-No. 2021-001512-28Funding StatementSupported by the German Federal Ministry of Education and Research (BMBF) Forschungsnetzwerk der Universitaetsmedizin zu Covid-19 COVIM - FKZ: 01KX2021 (to L.E.S., V.M.C., F.K., C.D., N.S.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:EICOV was approved by the ethics committee (IRB) of Charite - Universitaetsmedizin Berlin (EA4/245/20) and COVIM (EudraCT-No. 2021-001512-28) was approved by the Federal Institute for Vaccines and Biomedicines (Paul Ehrlich Institute) and by the Ethics committee of the state of Berlin.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available upon reasonable request.